Skip to main content

Table 6 Surgical results and overall response

From: Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

  Dose level  
  1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
Surgery?     
  No 1 (25%) 2 (15%) 3 (43%) 6 (25%)
  Yes 3 (75%) 11 (85%) 4 (57%) 18 (75%)
If so:     
  R0 2 (67%) 8 (73%) 4 (100%) 14 (78%)
Grading     
  G2   3 (27%) 1 (25%) 4 (22%)
  G3 2 (67%) 4 (36%) 2 (50%) 8 (44%)
  Information missing 1 (33%) 4 (36%) 1 (25%) 6 (33%)
Response prior to surgery (RECIST)     
  N 3 (100%) 12 (100%) 7 (100%) 22 (100%)
  PR 2 (67%) 3 (25%) 2 (29%) 7 (32%)
  SD   5 (42%) 2 (29%) 7 (32%)
  PD 1 (33%) 2 (17%) 2 (29%) 1 (5%)
  NK/ND   2 (17%) 1 (14%) 2 (9%)
Staging prior to surgery (UICC)     
  N 4 (100%) 12 (100%) 7 (100%) 23 (100%)
  II A   4 (33%) 1 (14%) 5 (229%)
  II B   1 (8%) 1 (14%) 2 (9%)
  III 3 (75%) 4 (33%) 2 (29%) 9 (39%)
  IV    1 (14%) 1 (4%)
  NK/ND 1 (25%) 3 (25%) 2 (29%) 6 (26%)
Pathologic response [15]     
  N 3 (100%) 11 (100%) 4 (100%) 18 (100%)
  CR   4 (36%) 2 (50%) 6 (33%)
  PR 1 (33%) 4 (36%) 2 (50%) 7 (39%)
  SD   1 (9%)   1 (6%)
  PD 1 (33%) 1 (9%)   2 (11%)
  NK/ND 1 (33%) 1 (9%)   2 (11%)
Staging after surgery (UICC)     
  N 3 (100%) 11 (100%) 4 (100%) 18 (100%)
  0   2 (18%) 1 (25%) 3 (17%)
  I   1 (9%) 1 (25%) 2 (11%)
  II A 1 (33%) 2 (18%)   3 (17%)
  II B 1 (33%) 2 (18%) 2 (50%) 5 (28%)
  III   1 (9%)   1 (6%)
  NK/ND 1 (33%) 3 (27%)   4 (22%)